New antibody combo takes on tough colorectal cancer
NCT ID NCT07649655
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called EMB-01, a bispecific antibody that targets two cancer-related proteins, combined with standard chemotherapy. About 120 adults with advanced colorectal cancer that cannot be surgically removed will receive the combination. The main goals are to find a safe dose and check for early signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EMB-01 (a bispecific antibody targeting EGFR and cMET) combined with chemotherapy (irinotecan, TAS-102, mFOLFOX6, or FOLFIRI)
What this could lead to
If successful, this could point toward a new treatment option for advanced colorectal cancer that has spread or cannot be removed by surgery.
What could go wrong
This is an early Phase 1 trial with only 120 participants, so safety and effectiveness are not yet proven. The combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE/METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••